Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 294

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 294
---
ANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 1:- GENERAL
(Cont.)

The Company expects
to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business
plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the
required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior
to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many
years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could
adversely impact the Company.

As of December 31,
2024, the Company had cash, cash equivalents, short-term deposits and restricted deposits of $62,855. During the year ended December 31,
2024, the Company incurred a net loss of $31,750and had negative cash flows from operating activities of $19,783. In addition, the Company
had an accumulated deficit of $147,509on December 31, 2024. The Company believes that its existing capital resources will be adequate
to satisfy its expected liquidity requirements for the foreseeable future.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements
are prepared according to United States generally accepted accounting principles (“ U. S. GAAP”). The significant accounting policies
are applied in the preparation of the financial statements on a consistent basis, as follows:

  Use of estimates for the preparation of financial statements:  

The preparation of
the consolidated financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect
the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates
estimates, including those related to fair values of warrants, fair values of share-based awards, deferred taxes, and contingent liabilities.
Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of
which form the basis for making judgments about the carrying values of assets and liabilities.

These estimates,
judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements,
and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

  Consolidated financial statements in U. S. dollars:  

The accompanying
consolidated